GleamWall
中文EN

EIKN Eikon Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1861123 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets45.6%
Debt / equity0.00x
Current ratio7.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue——————
R&D expense$71.83M$75.46M$70.05M$59.31M$69.19M$56.59M
SG&A expense$18.73M$17.93M$17.29M$15.44M$40.45M$14.80M
Operating income-$90.55M-$93.39M-$87.34M-$74.75M-$109.64M-$71.38M
Net income-$86.11M-$88.41M-$82.96M-$71.14M-$105.21M-$68.24M
EBITDA-$85.55M-$88.29M-$82.12M-$69.25M-$105.44M-$67.59M
EPS (basic)-1.59-1.63-2.46-24.24-36.94-26.91
EPS (diluted)-1.59-1.63-2.46-24.24-36.94-26.91
Weighted avg. shares (diluted)54.17M54.14M33.70M2.93M2.85M2.77M
Banking
Net interest income$4.49M$5.04M$4.38M$3.61M$4.43M$3.16M
Balance sheet
Cash & equivalents$98.48M$142.61M$161.15M$104.87M$136.56M$204.58M
Short-term investments$363.24M$388.56M$351.03M———
Current assets$478.12M$546.98M$529.50M———
PP&E, net$128.56M$133.07M$138.07M———
Total assets$706.20M$779.57M$850.83M———
Current liabilities$66.27M$55.30M$45.06M———
Total liabilities$321.91M$313.07M$300.15M———
Shareholders' equity$384.29M$466.50M$550.67M-$804.35M-$737.50M-$640.14M
Shares outstanding54.18M54.15M54.14M———
Cash flow statement
Operating cash flow-$69.19M-$64.96M-$89.80M-$59.53M-$32.74M-$54.52M
Capital expenditure$419,000$251,000$262,000$2.60M$21.72M$22.36M
Free cash flow-$69.61M-$65.21M-$90.06M-$62.14M-$54.45M-$76.88M
Investing cash flow$24.94M$46.43M-$203.22M$27.68M-$35.88M-$213.85M
Financing cash flow$157,000$25,000$349.31M$211,000$519,000$350.23M
Depreciation & amortization$5.00M$5.10M$5.21M$5.50M$4.20M$3.79M
Stock-based compensation$3.75M$4.22M$2.78M$3.99M$7.21M$2.97M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.